Want to see IMMP full AI Analyst Report?
IMMP Stock Chart & Stats
$0.38
>-$0.01(-0.08%)
At close: 4:00 PM EDT
$0.38
>-$0.01(-0.08%)
Day’s Range― - ―
52-Week Range$3.06 - $70.58
Previous CloseN/A
Volume89.72K
Average Volume (3M)25.32K
Market Cap
$23.84M
Enterprise Value$14.45M
Total Cash (Recent Filing)$68.88M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Feb 25, 2027EPS Estimate
-1.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.70
Shares Outstanding7,370,551
10 Day Avg. Volume18,590
30 Day Avg. Volume25,322
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.44
Price to Sales (P/S)6.23
P/FCF Ratio-1.63
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue0.87
Enterprise Value/Gross Profit-0.47
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$30.00Price Target Upside7794.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.49
Revenue Forecast (FY)$2.74M
Bulls Say, Bears Say
Bulls Say
Proprietary LAG-3 PlatformA proprietary LAG-3 platform gives Immutep a focused technological foundation across multiple immunotherapy programs. If clinical development succeeds, the shared mechanism and combination strategy could support several indications and create partnership or commercialization opportunities beyond a single asset.
Improving Revenue And Gross MarginMeaningful revenue growth and a sharp gross-margin recovery indicate improving commercialization or licensing economics compared with prior periods. Although earnings remain negative, stronger top-line performance and gross profitability can improve the company’s ability to fund development and demonstrate future operating leverage.
Low Financial LeverageVery low debt reduces solvency and refinancing pressure while preserving flexibility for clinical investment and business development. The company is therefore less exposed to interest obligations than a highly leveraged biotech, allowing more of its available resources to remain directed toward pipeline advancement.
Bears Say
Large And Expanding LossesImmutep has not established sustainable profitability: losses widened despite higher revenue, and the deeply negative net margin shows that operating costs remain far above current income. Continued losses can delay self-funded growth and increase dependence on future financing, partnerships, or successful clinical outcomes.
Persistent Cash BurnNegative operating and free cash flow indicate that ongoing research and clinical activities consume substantial cash rather than funding themselves. The further deterioration in FY2026 raises the importance of financing access and partnership receipts, while reducing the company’s ability to absorb development setbacks internally.
Shrinking Shareholder CapitalThe steep decline in equity shows that accumulated losses are consuming shareholder capital, even though debt remains low. A smaller capital base reduces financial resilience and may increase reliance on future equity issuance or other funding, creating potential dilution and limiting strategic flexibility.
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $3.06 and its highest was $70.58 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $23.84M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 25, 2027 which is in 124 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Sep 02, 2026. The company reported -$3.349 earnings per share for the quarter, missing the consensus estimate of -$0.516 by -$2.833.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -1.45.
How many shares outstanding does Immutep have?
Immutep has 7,370,551 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$3.349 in its last earnings report, missing expectations of -$0.516. Following the earnings report the stock price went up 3.152%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
IMMP Stock 12 Month Forecast
Average Price Target
$30.00
▲(7794.74% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.38% Mutual Funds
― Other Institutional Investors
99.08% Public Companies and
Individual Investors